Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13858209 | 0.76 | SIGMAR1 (0.41) | SIGMAR1KCNH2BCHE | |
| SCHEMBL9171988 | 0.76 | CSNK1E (0.49) | CSNK1ESIGMAR1EPHX2PKMKCNH2 | |
| SCHEMBL23718107 | 0.75 | CSNK1E (0.47) | CSNK1ESIGMAR1EPHX2PKMKCNH2 | |
| SCHEMBL44484 | 0.73 | CSNK1E (0.41) | CSNK1ESIGMAR1KCNH2CNR2BCHE | |
| SCHEMBL3282362 | 0.73 | SIGMAR1 (0.47) | CSNK1ESIGMAR1EPHX2PKMKCNH2 | |
| SCHEMBL5275290 | 0.72 | CSNK1E (0.40) | CSNK1ESIGMAR1EPHX2PKMKCNH2 | |
| SCHEMBL15070153 | 0.72 | CSNK1E (0.40) | CSNK1ESIGMAR1KCNH2CNR2BCHE | |
| SCHEMBL5698127 | 0.72 | CSNK1E (0.53) | CSNK1ESIGMAR1EPHX2KCNH2CNR2 | |
| SCHEMBL3757647 | 0.72 | CRHR1 (0.36) | CSNK1ESIGMAR1KCNH2CYP19A1 | |
| SCHEMBL13109023 | 0.70 | SIGMAR1 (0.41) | SIGMAR1KCNH2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7847117-B2 | Process for preparing alkyl(methoxymethyl)trimethylsilanylmethylamines | WACKER CHEMIE AG (DE) | 2010-12-07 | — | — | US | disclosed |
| EP-2050754-B1 | Method for manufacturing alkyl-methoxymethyl-trimethylsilanylmethyl amines | WACKER CHEMIE AG (DE) | 2010-09-15 | — | — | EP | disclosed |
| EP-2050754-A1 | Method for manufacturing alkyl-methoxymethyl-trimethylsilanylmethyl amines | Wacker Chemie AG (DE) | 2009-04-22 | — | — | EP | disclosed |
| US-20090036700-A1 | Process For Preparing Alkyl(Methoxymethyl)Trimethylsilanylmethylamines | WACKER CHEMIE AG (DE) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036700-A1 | Process For Preparing Alkyl(Methoxymethyl)Trimethylsilanylmethylamines | PNMT, TET2, HNMT | CSNK1E 1550/4885SIGMAR1 374/4885EPHX2 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.